One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.
Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …
Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.
These two pharma stocks all have upside of over 100% say top Wall Street analysts.